My Profile

Search abstracts

Lewis Sheiner

Stockholm, Sweden

Montreux, Switzerland

Budapest, Hungary

Lisboa, Portugal

Hersonissos, Crete, Greece

Alicante, Spain

Glasgow, Scotland

Venice, Italy

Athens, Greece

Berlin, Germany

St. Petersburg, Russia

Marseille, France

København, Denmark

Brugge/Bruges, Belgium

Pamplona, Spain

Uppsala, Sweden

Verona, Italy

Paris, France

Basel, Switzerland

Salamanca, Spain

Saintes, France

Wuppertal, Germany

Glasgow, Scotland

Sandwich, UK

Frankfurt, Germany

Greenford, UK

Paris, France

Basel, Switzerland

Printable version

Monday June 23
08:45-09:00 Welcome and Introduction
09:00-10:20 Oral session I Free communications chair: Leon Aarons
Per Olsson A population PK/PD model for the irreversible inhibition of 5alpha- reductase types 1 and 2, and the effects on plasma dihydrotestosterone levels
Rik de Greef The use of compliance data in the analysis of a clinical trial of antiretroviral drugs in HIV+ individuals
   Namik Taright Non-stationarity of kinetic parameters in multi-occasion designs
   J. Wang Two-stage procedures for the analysis of cross-over trials using pharmacokinetic and pharmacodynamic models
   Christine Veyrat-Follet Is ipecac model a good predictor of concentration-efficacy response to ondansetron in patients?
10:20-10:50 Coffee
10:50-12:40 Oral session II Categorical variables chair: Ferdie Rombout
Stuart Beal Analyzing odd type data using NONMEM
Adrian Dunne Population analysis of ordinal categorical data.
  Jon Wakefield  The Bayesian approach to categorical responses
12:40-14:00 Lunch
14:00-15:30 Oral session III Clinical applications chair: Duncan Jodrell
Etienne Chatelut Subsequent developments of formulas designed for predicting carboplatin clearance in adults and in children
Alan Boddy Population pharmacokinetics of etoposide in children
Jean-Louis Steimer Mixed-effects modelling of the dose-AUC relationship of saquinavir single dose in healthy subjects
David Lunn The pharmacokinetics of saquinavir: a Markov chain Monte-Carlo population analysis
15:30-16:00 Coffee/Tea
16:00-17:30 Oral session IV New Developments and Softwares chair: France Mentré
Anthony Hunt A paradigm for validating methodologies to simulate clinical trials validation of pharmacodynamic predictions
Nicky Best New developments in the BUGS software for Bayesian modelling
Roberto Gomeni NPML-FIT: a graphical nonparametric population modelling program
  Niclas Jonsson  XPOSE 2.0 - an SPLUS based population model building aid for NONMEM

Tuesday 24 June
09:00-10:00 Oral session V Discussion Topics I chair: Janet Wade
Don Nicholls Experiences with genotype and phenotype information in mixed effects modelling
Niclas Jonsson Covariate model building in population analysis
Lutz Harnisch The estimation of drug-drug interactions in population pharmacokinetic trials
10:00-12:00 Poster and software session
12:00-13:15 Oral session VI Discussion Topics II chair: Janet Wade
Karin Fattinger The estimation of drug input rate functions by nonparametric subject- specific population deconvolution
Pascal Girard Undercompliance and population pharmacokinetics.
Mats Karlsson Assumption testing in population pharmacokinetic models
13:15 Closure followed by light lunch


Poster Presentations
Aarons L, Gupta, SK A mixed-effects modelling approach to the analysis of verapamil-GITS blood pressure data
Bleyzac N., Vial F., Allard-Latour B., Mouret J. , Jelliffe RW , Maire PH Contribution of nonparametric population pharmacokinetic software to the determination of diurnal variations of drug pharmacokinetic parameters
Dubruc C, Mesnil F, Thenot JP, Mentré F. Population pharmacokinetic analysis of mizolastine in healthy young volunteers and allergic patients using NONMEM
Ebelin M-E, Mentré F, Burtin P, Laplanche R Pharmacokinetic population analysis of SDZ ENA 713 and its metabolite in patients; relationships with efficacy, safety and tolerability
Frey, N., Laveille C., Kiefer Ph., Laudignon N, Jochemsen R. Population pharmacokinetics/pharmacodynamics of a new formulation of gliclazide in 224 type 2 diabetics.
Garcia MJ, Santos Buelga D, Otero Mj, Serrano J, Blanco B, Dominguez-Gil A. Population pharmacokinetics: effect of polytherapy on valproic acid clearance
Jonsson N and Karlsson M Covariate model building in population analysis using a bootstrap resampling procedure
Khan, AZ, Pitsiu, M., Aarons, LA, Parivar, K, Widman, M Population pharmacokinetic analysis of eltanolone
Larsson P, Weibull E, Pedersen S Estimation of bioavailability using a semi-simultaneous design
Laveille C., Frey N, Lerebours G, Resplandy G, Jochemsen R. Population pharmacokinetics-pharmacodynamics of a new specific bradycardic agent (S16257) and its metabolite (S 18982) evaluation of the drug/metabolite potency ratio
Modamio P, Jansat JM, Lastra CF, Marino EL Change in the analytical error function depending on the calibration curve range: implications for pharmacokinetic parameter estimation of carebastine.
Piotrovskij V., Van de Velde V., Van Pee A A population analysis of lubeluzole pharmacokinetics in healthy volunteers and patients with ischaemic stroke
du Preez M, Botha J, and McFadyen L A count model for analysing pk/pd data for theophylline in neonatal apnoea
Romano S, Falcao AC, Del Mar Fdz. De GattaM, Victoria Calvo M, Méndez E, Domínguez-Gil A, Lanao Pharmacokinetics of amikacin in intensive care unit patients: population analysis.
Rosario M, Sharp CA, Jodrell DI, Thomson AH Population pharmacokinetics of gentamicin in oncology patients
Rostami-Hodjegan A, Tucker GT On estimating half-life using population pharmacokinetics
Topping LP, Longford NT An alternative definition of individual bioequivalence
Tranchand B, Pobel C, Ardiet CJ, Parola JN, Ménard G Pharmacokinetic/dynamic modelling of neutropenic effect of melphalan using NONMEM associated with a cubic spline function
F. Trocóniz I, Naukkarinen T, Karlsson MO Population pharmacodynamic modelling of levodopa in Parkinsonian patients receiving the COMT inhibitor entacapone